1. A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy. Issue 4 (22nd December 2017) Authors: Mösges, R.; Kasche, E. M.; Raskopf, E.; Singh, J.; Sohlich, L.; Astvatsatourov, A.; Shah‐Hosseini, K.; Pirotton, S.; Haazen, L.; Durham, S. R.; Legon, T.; Zadoyan, G.; Shamji, M. H. Journal: Allergy Issue: Volume 73:Issue 4(2018) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients. Issue 6 (13th February 2018) Authors: Mösges, R.; Koch, A. F.; Raskopf, E.; Singh, J.; Shah‐Hosseini, K.; Astvatsatourov, A.; Hauswald, B.; Yarin, Y.; Corazza, F.; Haazen, L.; Pirotton, S.; Allekotte, S.; Zadoyan, G.; Legon, T.; Durham, S. R.; Shamji, M. H. Journal: Allergy Issue: Volume 73:Issue 6(2018) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial. Issue 9 (21st June 2018) Authors: Mösges, R.; Bachert, C.; Panzner, P.; Calderon, M. A.; Haazen, L.; Pirotton, S.; Wathelet, N.; Durham, S. R.; Bonny, M.‐A.; Legon, T.; von Frenckell, R.; Pfaar, O.; Shamji, M. H. Journal: Allergy Issue: Volume 73:Issue 9(2018) Page Start: 1842 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗